





September 17, 2021

Announce the formation of a business alliance with Fresenius Medical Care

We have formed a business alliance in the field of home dialysis in Japan with Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure.

JMS Co., Ltd. (address: Hiroshima, Japan, Representative Director: Hiroaki Okukubo) and Fresenius Medical Care Japan K.K. have reached a basic agreement on a business alliance in the field of home dialysis in Japan. Under the government promotion policy of home medical care, both parties will work together to expand our home dialysis business by providing services that meet the changing lifestyles and diversifying needs of patients with chronic kidney failure.

Dialysis therapy for chronic kidney failure patients mainly includes hemodialysis in hospital and home therapies. We are the only one company in Japan to manufacture and sell both of these products. Fresenius Medical Care is a leading company in the global dialysis market and has a rich product portfolio, in home therapies which has become increasingly popular in recent years, from peritoneal dialysis related products to home hemodialysis, as it provides high quality products to help patients choose the appropriate dialysis therapy according to their lifestyle. We have decided that it is not only high affinity with our dialysis business, but also the most suitable partner to create new innovation.

	Hemodialysis	Aiming to popularize home dialysis	
		Peritoneal dialysis	Home hemodialysis
<p><Types of Dialysis Therapy> Patients with chronic kidney failure receive dialysis therapy to get uremia out of the body</p> 		 <p>CAPD Continuous Ambulatory Peritoneal Dialysis</p>  <p>APD Automated Peritoneal Dialysis</p> <p>APD treatments are supported by a machine</p>	
Dialysis site	Hospital	Home or Work	Home
Main frequency	2-3 times a week	4-6 times a day	4-6 times a week

Background of Business Alliance

- The number of dialysis patients for chronic kidney failure in Japan is increasing by about 5,000 every year.
- In Japan, more than 90% of hemodialysis treatment is performed in hospitals.
- The number of patients who prefer home therapy with a high degree of freedom is increasing due to changes in lifestyle and diversification of needs.

Purpose and Content of the Business Alliance

- By forming a business alliance with Fresenius Medical Care, we will increase the penetration rate of home dialysis therapy in Japan and contribute to improving the QOL of dialysis patients.
- First, Fresenius Medical Care's home dialysis-related products will be added to the Company's product lineup to strengthen the product portfolio, and business collaboration will be promoted through cooperation in logistics operations, etc.
- Furthermore, the two companies plan to start discussions on initiatives such as the development and introduction of new technologies and products that meet the individual needs of dialysis patients.

Inquiries: JMS Co., Ltd. Corporate Planning Department E-mail: pub-bpd@jms.cc

Press Release

Fresenius Medical Care Japan Co., Ltd. Profile

(1) Name	Fresenius Medical Care Japan K.K.
(2) Location	2-7 Kaimo, Buzen, Fukuoka, 828-0045, Japan
(3) Date Established	October, 1993
(4) Representative	Jean Desombre
(5) Capital	80 million yen (Fresenius Medical Care AG & Co.KGaA 100% ownership)
(6) Business	Import, manufacture and sale of artificial dialysis machines and dialyzer for dialysis Import, export, manufacture and sale of peritoneal dialysate and related medical devices
About Fresenius Medical Care	<p>Fresenius Medical Care is the world's leading provider of products and services for people with chronic kidney failure of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,092 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 346,553 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).</p> <p>For more information visit the Company's website at https://www.freseniusmedicalcare.com https://www.freseniusmedicalcare.asia</p>

The forward-looking statements contained in this release are based on currently available information and include a variety of potential risks and uncertainties, including major changes in social conditions. Please note that this information is as of the date of issue and is subject to change in the future.